Nath Bio-Genes (India) Limited has announced a board meeting scheduled for May 4, 2026, to review and approve key financial matters for the fourth quarter and financial year ended March 31, 2026. The company issued the intimation on April 25, 2026, in compliance with Regulation 29 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Board Meeting Agenda

The board meeting will address several critical matters for the company's financial year 2025-26:

Trading Window Closure

In accordance with the company's Code of Conduct for prevention of Insider Trading, Nath Bio-Genes has implemented a trading window closure. The trading window was closed from March 31, 2026, and will remain closed until May 6, 2026, when it will reopen following the board meeting.

Regulatory Compliance

The board meeting intimation was issued pursuant to Regulations 29 and 33 of the SEBI Listing Regulations 2015. Company Secretary Dhiraj Rathi signed the notice digitally on April 25, 2026, at 20:11:30 hours. The announcement was communicated to both major stock exchanges where the company is listed.

The upcoming board meeting represents a significant milestone for Nath Bio-Genes as it concludes the financial year 2025-26 with the approval of audited results and potential dividend considerations for shareholders.

Nath bio-genes (I) Ltd. has submitted its compliance certificate for the quarter ended 31st March 2026 to both BSE Limited and National Stock Exchange of India Ltd. The submission fulfills the regulatory requirements under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Details

The compliance certificate was received from M/s Bigshare Services Pvt. Ltd., which serves as the Registrar and Share Transfer Agent for the company. The certificate was submitted on 15th April 2026 by Amol Gupta, Chief Financial Officer of Nath Bio-Genes (India) Limited.

Certificate Confirmation

Bigshare Services Pvt. Ltd. confirmed in their certificate dated 06/04/2026 that securities received from depository participants for dematerialization up to 31st March 2026 were properly confirmed to the depositories. The registrar verified that all securities comprised in the certificates have been listed on the stock exchange where the earlier issued securities are listed.

Dematerialization Process Compliance

The certificate confirms that security certificates received for dematerialization have been mutilated and cancelled after due verification by the depository participant. Additionally, the names of the depositories have been substituted in the register of members as registered owners within 15 days of receipt of certificate of securities, ensuring full compliance with regulatory requirements.

Company Information

Nath Bio-Genes (I) Ltd. operates under CIN L01110MH1993PLC072842 and maintains offices in Aurangabad and Mumbai. The company's securities are traded on BSE under code 537291 and on NSE under the symbol NATHBIOGEN.